Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 16144807)

1.

Computational methods for the design of effective therapies against drug resistant HIV strains.

Beerenwinkel N, Sing T, Lengauer T, Rahnenführer J, Roomp K, Savenkov I, Fischer R, Hoffmann D, Selbig J, Korn K, Walter H, Berg T, Braun P, Fätkenheuer G, Oette M, Rockstroh J, Kupfer B, Kaiser R, Däumer M.

Bioinformatics. 2005 Nov 1;21(21):3943-50. Epub 2005 Sep 6. Review.

2.

Bioinformatics approach to predicting HIV drug resistance.

Cordes F, Kaiser R, Selbig J.

Expert Rev Mol Diagn. 2006 Mar;6(2):207-15. Review.

PMID:
16512780
3.

Bioinformatics-assisted anti-HIV therapy.

Lengauer T, Sing T.

Nat Rev Microbiol. 2006 Oct;4(10):790-7.

PMID:
16980939
4.

A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.

Wang D, Larder B, Revell A, Montaner J, Harrigan R, De Wolf F, Lange J, Wegner S, Ruiz L, Pérez-Elías MJ, Emery S, Gatell J, D'Arminio Monforte A, Torti C, Zazzi M, Lane C.

Artif Intell Med. 2009 Sep;47(1):63-74. doi: 10.1016/j.artmed.2009.05.002. Epub 2009 Jun 12.

PMID:
19524413
5.

Drug-resistant human immunodefiency virus.

Kozal MJ.

Clin Microbiol Infect. 2009 Jan;15 Suppl 1:69-73. doi: 10.1111/j.1469-0691.2008.02687.x. Review.

6.

The development of artificial neural networks to predict virological response to combination HIV therapy.

Larder B, Wang D, Revell A, Montaner J, Harrigan R, De Wolf F, Lange J, Wegner S, Ruiz L, Pérez-Elías MJ, Emery S, Gatell J, Monforte AD, Torti C, Zazzi M, Lane C.

Antivir Ther. 2007;12(1):15-24.

PMID:
17503743
7.

Vaccination against drug resistance in HIV infection.

Boberg A, Isaguliants M.

Expert Rev Vaccines. 2008 Feb;7(1):131-45. doi: 10.1586/14760584.7.1.131. Review.

PMID:
18251699
8.

Methods for optimizing antiviral combination therapies.

Beerenwinkel N, Lengauer T, Däumer M, Kaiser R, Walter H, Korn K, Hoffmann D, Selbig J.

Bioinformatics. 2003;19 Suppl 1:i16-25.

9.

Combining drug and immune therapy: a potential solution to drug resistance and challenges of HIV vaccines?

Endsley AN, Salama NN, Ho RJ.

Curr HIV Res. 2008 Sep;6(5):401-10. Review.

PMID:
18855650
10.

A game theoretical approach to optimal control of dual drug delivery for HIV infection treatment.

Wu J, Zhang M.

IEEE Trans Syst Man Cybern B Cybern. 2010 Jun;40(3):694-702. doi: 10.1109/TSMCB.2010.2040616. Epub 2010 Feb 18.

PMID:
20176541
11.

When to initiate HIV therapy: a control theoretic approach.

Jeffrey AM, Xia X, Craig IK.

IEEE Trans Biomed Eng. 2003 Nov;50(11):1213-20.

PMID:
14619991
12.

HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.

Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, Harzic M, Tamalet C, Meyer L, Rouzioux C, Chaix ML; French PRIMO Cohort Study Group (ANRS CO 06).

AIDS. 2006 Jan 9;20(2):159-70.

PMID:
16511408
13.

Mutation and control of the human immunodeficiency virus.

Stengel RF.

Math Biosci. 2008 Jun;213(2):93-102. doi: 10.1016/j.mbs.2008.03.002. Epub 2008 Mar 20.

PMID:
18439629
14.

Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan.

Chang SY, Chen MY, Lee CN, Sun HY, Ko W, Chang SF, Chang KL, Hsieh SM, Sheng WH, Liu WC, Wu CH, Kao CL, Hung CC, Chang SC.

J Antimicrob Chemother. 2008 Mar;61(3):689-93. doi: 10.1093/jac/dkn002. Epub 2008 Jan 28.

15.

GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

Koh Y, Das D, Leschenko S, Nakata H, Ogata-Aoki H, Amano M, Nakayama M, Ghosh AK, Mitsuya H.

Antimicrob Agents Chemother. 2009 Mar;53(3):997-1006. doi: 10.1128/AAC.00689-08. Epub 2008 Oct 27.

16.

Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs.

Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, Schechter M.

J Med Virol. 2008 Apr;80(4):565-76. doi: 10.1002/jmv.21034. Review.

PMID:
18297706
17.

Optimization of HAART with genetic algorithms and agent-based models of HIV infection.

Castiglione F, Pappalardo F, Bernaschi M, Motta S.

Bioinformatics. 2007 Dec 15;23(24):3350-5. Epub 2007 Oct 17.

18.

An overview of the human immunodeficiency virus featuring laboratory testing for drug resistance.

Scosyrev E.

Clin Lab Sci. 2006 Fall;19(4):231-45; quiz 246-9. Review.

PMID:
17181129
19.

Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.

Metzner KJ, Allers K, Rauch P, Harrer T.

AIDS. 2007 Mar 30;21(6):703-11.

PMID:
17413691
20.

Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability.

Ko JH, Kim WH, Chung CC.

IEEE Trans Biomed Eng. 2006 Mar;53(3):380-6.

PMID:
16532764
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk